Prontogest 400 mg 30 pessary

Tradename:

Prontogest

Prontogest

Composition:

Each pessary contains:

Progesterone 400 mg

Auxiliary components:

Solid fat, stearolpolyxylglucerides, sorbitol acid, cocoa butter, purified water.

Properties:

The active ingredient of Prontogest@ is progesterone, which is identical to the natural hormone of the corpus luteum of the ovary. By binding to receptors on the surface of cells of target organs, it penetrates into the nucleus, where it activates DNA and stimulates RNA synthesis. Promotes the transition of the uterine mucosa from the proliferation phas caused by the follicular hormone estradiol into the secretory phase. After fertilization, it promotes the transition to a state necessary for the development of a fertilized egg.

Reduces the excitability and contractility of the muscles of the uterus and fallopian tubes. Promotes the formation of a normal endometrium. Stimulates the development of the terminal elements of the mammary gland, induces lactation. By stimulating protein lipase, it increases fat stores, increases glucose utilization. By increasing the concentration of basal and stimulated insulin, promotes the accumulation of glycogen in the liver, increases the production of pituitary gonadotropic hormones; reduces azotemia, increases the excretion of nitrogen in the urine.

Indications:

@ MHT in case of progesterone deficiency with non-functioning (absent) ovaries (egg donation);

@ prevention (prophylaxis) of premature birth in women at risk (with shortening of the cervix and / or the presence of anamnestic data of premature birth and / or premature rupture of membranes);  support of the luteal phase during

preparation for in vitro fertilization;  support of the luteal phase in a spontaneous or induced menstrual cycle; premature menopause;

MHT (in combination with estrogencontaining drugs);

(9 infertility due to luteal insufficiency;  threatening abortion or prevention of habitual abortion due to progesterone deficiency.

Method of administration and dosage:

Applied intravaginally or anally, 200 mg or 400 mg twice a day. For premenstrual syndrome, start treatment on the 14th day of the menstrual cycle and continue treatment until the onset of menstruation. If symptoms are present during ovulation, start treatment on day 12.

Contraindications:

• deep vein thrombosis, thrombophlebitis; thromboembolic disorders (pulmonary embolism, myocardial infarction, stroke), intracranial hemorrhage, or a history of

these conditions / diseases;  vaginal bleeding of unknown origin;

• incomplete abortion;
• porphyria;

(9 established or suspected malignant neoplasms of the mammary glands and genitals;

• severe liver diseases (including cholestatic jaundice, hepatitis, Dubin-Johnson, Rotor syndromes, malignant liver tumors) at present or in history; age up to 18 years (efficacy and safety have not been established);
• period of breastfeeding;
• hypersensitivity to progesterone or any of the auxiliary components of the drug. With care: diseases of the cardiovascular system, arterial hypertension, chronic renal failure, diabetes mellitus, bronchial asthma, epilepsy, migraine, depression, hyperlipoproteinemia, liver dysfunctions of mild and moderate severity, photosensitivity; Il and Ill trimesters of pregnancy.

Precautions:

The drug should be taken with caution in patients with diseases and conditions that can be aggravated by fluid retention (arterial hypertension, cardiovascular diseases, chronic renal failure, epilepsy, migraine, bronchial asthma); in patients with diabetes mellitus; impaired liver function of mild to moderate severity; photosensitivity.

Patients with a history of depression should be monitored, and if severe depression develops, the drug should be discontinued. Patients with concomitant cardiovascular diseases or a history of them should also be monitored periodically by a doctor. The use of the drug after the first trimester of pregnancy can cause the development of cholestasis. Long-term progesterone treatment requires regular medical examinations (including liver function tests); treatment should be canceled in case of deviations from the normal parameters of liver function tests or cholestatic jaundice. With the use of progesterone, a decrease in glucose tolerance and an increase in the need for insulin and other hypoglycemic drugs in patients with diabetes mellitus are possible.

Side effects:

It was reported about individual cases of the development of reactions of local intolerance to the components of the drug (in particular, soy lecithin) in the form of hyperemia of the vaginal mucosa, burning, itching, oily discharge. Systemic side effects with intravaginal use of the drug in recommended doses, in particular, drowsiness or dizziness (observed with oral administration of the drug), were not observed.

Storage method:

At a temperature not higher than 30 degrees.

Packaging:

The cardboard box contains 6 blisters of 5 vaginal pessaries.